About Devon Robotics

Devon Robotics is a medical robotics company that is revolutionizing the way hazardous drugs and life-critical IV medications are prepared. The company is the exclusive distributor of Health Robotics’ CytoCare™ and i.v.STATION™ robots in North America and the Caribbean Islands. CytoCare™ is the world’s first and only automated robotic system for the safe preparation of hazardous, patient-specific cancer therapy medications and IV admixtures. i.v.STATION™ is an automated robotic solution for the safe compounding of life-critical IV medications. Devon Robotics is a Devon International Group company headquartered in King of Prussia, Pennsylvania.

The Devon International Group (DIG) is a multi-national group of businesses whose goal is to provide, through its companies, products and services that are unique, innovative and affordable. Its companies operate across the world and span the healthcare, information technology, manufacturing, and international trading industries. DIG embraces an entrepreneurial spirit that encourages employee creativity to fuel the advancement of each company's products and services and takes advantage of emerging business opportunities that a "flat world" economy presents. DIG's headquarters are in King of Prussia, Pennsylvania, and the Group has offices in Ireland, London, Lithuania, Bangalore, India, Shanghai, and Beijing.

Health Robotics (www.health-robotics.com) is the global leading supplier of life-critical intra-venous medication preparation, compounding, and dispensing Robots, with forty-five-times more units sold than all of its competitors combined, and providing healthcare facilities in four continents with robotics technology and software automation solutions. The world-leading solutions CytoCare [hazardous IVs] and i.v.STATION [non-hazardous IVs] have and will greatly contribute to ease global hospitals’ and clinics’ growing pressures to improve patient safety through the effective and efficient production of sterile, accurate, and ready-to-administer IVs, to eliminate life-threatening drug-exchange errors, to decrease other medication errors and contamination risks, and to work more efficiently, increase throughput, reduce waste, and contain costs.